Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
The bill requires HHS to withdraw the current mifepristone REMS and reapprove a Risk Evaluation and Mitigation Strategy identical to the June 2011 REMS within 90 days, and forbids any different REMS. It creates a federal civil cause of action against telehealth providers, pharmacies, or anyone who knowingly imports or transports mifepristone in violation of federal law when that use causes bodily or mental-health harm.
Left emphasizes reduced access and reproductive-rights harms
Relative to its intended legislative type, this bill is a clearly structured substantive policy bill that prescribes specific regulatory outcomes and creates private enforcement avenues while amending identified statutory provisions.
The bill requires HHS to withdraw the current mifepristone REMS and reapprove a Risk Evaluation and Mitigation Strategy identical to the June 2011 REMS within 90 days, and forbids any different REMS.
It creates a federal civil cause of action against telehealth providers, pharmacies, or anyone who knowingly imports or transports mifepristone in violation of federal law when that use causes bodily or mental-health harm.
The bill also amends the FDCA to bar importation of mifepristone into the United States, including mailing to individuals.
Narrow but polarizing; likely to provoke procedural resistance, amendments, and legal challenges reducing enactment odds.
Relative to its intended legislative type, this bill is a clearly structured substantive policy bill that prescribes specific regulatory outcomes and creates private enforcement avenues while amending identified statutory provisions. It contains concrete deadlines and direct statutory edits that integrate with existing law.
Left emphasizes reduced access and reproductive-rights harms
These are examples from the analysis, not a ranked list of the most-affected groups.
Left emphasizes reduced access and reproductive-rights harms
Likely strongly opposed.
They would view the bill as a regulatory rollback that restricts access to medication abortion, criminalizes or chills telehealth and mail-order options, and exposes providers and intermediaries to broad liability.
They would emphasize evidence on mifepristone safety and worry about disproportionate impacts on low-income and rural patients.
Mixed/uncertain.
They will weigh patient safety oversight against access harms.
Centrists will want independent scientific justification for reverting to the 2011 REMS and clarity limiting liability to willful or illegal conduct.
Likely supportive.
This persona will view the bill as restoring safety protections and preventing mail-order or foreign-sourced abortion drugs.
They will welcome the import ban and civil liability provisions as deterrents and accountability mechanisms for telehealth and distributors who violate mailing laws.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Narrow but polarizing; likely to provoke procedural resistance, amendments, and legal challenges reducing enactment odds.
The bill has not accumulated any surfaced votes yet.
Left emphasizes reduced access and reproductive-rights harms
Narrow but polarizing; likely to provoke procedural resistance, amendments, and legal challenges reducing enactment odds.
Relative to its intended legislative type, this bill is a clearly structured substantive policy bill that prescribes specific regulatory outcomes and creates private enforcement avenues while amending identified statuto…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.